|1.||Witherell, Gary: 1 article (05/2002)|
05/01/2002 - "XTL-001 showed viral neutralization activity in the Trimera model for HBV infection and was several thousand-fold more active than current antibody-based therapies. "
05/01/2002 - "XTL-001, a combination of two human high-affinity monoclonal antibodies with affinity to different regions of the HBV surface antigen (HBsAg), is under development by XTL Biopharmaceuticals as a potential passive immunotherapy for HBV infection. "
|1.||Hepatitis B Surface Antigens (HBsAg)
|2.||Surface Antigens (Surface Antigen)